Clodronate Disodium Tablets

This product is a bone metabolism regulator that can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts.

Clodronate disodium.

White or off-white tablets.

1. Hypercalcemia complicated by malignant tumors. 2. Bone pain caused by osteolytic cancer metastasis. 3. Can prevent or delay osteolytic bone metastasis of malignant tumors. 4. Various types of osteoporosis.

1. Paget's disease: 300 mg/day, intravenous drip for more than 3 hours, for 5 days, then oral administration. 2. Hypercalcemia: 300 mg/day, intravenous drip for 3 to 5 days or 1.5 g intravenous drip once, then oral administration after blood calcium returns to normal.

1. Dizziness and fatigue may occur in a few cases, but they usually disappear with continued treatment. 2. Adverse reactions such as increased serum lactate dehydrogenase and other liver enzyme levels, leukopenia, and abnormal renal function may sometimes occur.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe renal impairment and osteomalacia are prohibited from using this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

Not yet clear.

Sealed, store in a dry place.

0.2 g (calculated as CH2Cl2Na206P2)

24 months

Nanjing Pharmaceutical FACTORY Co., Ltd.

• Founded in:

  1991-07-11

• Address:

  No. 26, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192134908655F

• Registered Funds:

  200.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view